Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 41 |
| Active Pipeline (Recruiting Now) | 35 (20) |
| Completed vs Stopped Early | 4 / 2 (4.9%) |
| Median Closed Actual Enrollment | 295 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong | 10 |
| Jiangsu Province Hospital | Nanjing, Jiangsu | 7 |
| The first affiliated hospital of Zhengzhou University | Zhengzhou, Henan | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07564466 | A Study of SKB571 in Participants With Gastrointestinal Tumors | Phase II | RECRUITING |
| NCT07622186 | A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) | Phase II | RECRUITING |
| NCT07019675 | A Study of SKB518 in Patients With Lung Cancer | Phase II | RECRUITING |
| NCT07700667 | SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma | Phase II | RECRUITING |
| NCT06711900 | A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 | Phase III | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Sichuan Kelun-Biotech Biopharmaceutical Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.